Table 1.
Baseline characteristics of patients with clear cell renal cell carcinoma included in the next-generation sequencing analysis
| First-line everolimus N = 109 |
First-line sunitinib N = 111 |
Biomarker analysis set N = 220 |
|
|---|---|---|---|
| Sex, n (%) | |||
| Male | 80 (73) | 88 (79) | 168 (76) |
| Female | 29 (27) | 23 (21) | 52 (24) |
| Age, mean (range; yr) | 62 (21–89) | 62 (32–84) | 62 (21–89) |
| Race, n (%) | |||
| White | 78 (72) | 90 (81) | 168 (76) |
| Black | 1 (1) | 3 (3) | 4 (2) |
| Asian | 20 (18) | 10 (9) | 30 (14) |
| Other | 10 (9) | 8 (7) | 18 (8) |
| KPS, n (%) | |||
| ≥90 | 28 (26) | 28 (25) | 56 (25) |
| 80 | 20 (18) | 12 (11) | 32 (14) |
| ≤70 | 10 (9) | 12 (11) | 22 (10) |
| Missing | 51 (47) | 59 (53) | 110 (50) |
| Nephrectomy, n (%) | |||
| Yes | 98 (90) | 101 (91) | 199 (90) |
| No. of metastatic sites, n (%) | |||
| 0 | 1 (<1) | 2 (2) | 3 (1) |
| 1 | 21 (19) | 28 (25) | 49 (22) |
| ≥2 | 87 (80) | 81 (73) | 168 (76) |
| MSKCC risk group, n (%) | |||
| Favorable | 41 (38) | 53 (48) | 94 (43) |
| Intermediate | 56 (51) | 50 (45) | 106 (48) |
| Poor | 12 (11) | 8 (7) | 20 (9) |
| LDH, median (range; U/l) | 169 (102–860) | 159 (106–669) | 163 (102–860) |
| Median PFS1L (mo), (95% CI) | 8.3 (5.4–10.7) | 10.8 (8.1–12.9) | — |
KPS = Karnofsky performance status; LDH = lactate dehydrogenase; MSKCC = Memorial Sloan Kettering Cancer Center; PFSL1 = progression-free survival first-line.